Andrew A Welcher

This inventor holds 20 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 4 EPO patents, primarily in Immunotherapy Research. Top assignees: Amgen Inc., Medarex Inc., E. R. Squibb Sons, Inc.. Active years: 1997-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrew A Welcher. Retrieved from https://idiyas.com/inventor/andrew-a-welcher

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 20 (Patent Applications = 4)

% Patents Active = 70.0

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 3.7

ph-index = 4

Forward Citations = 129(Granted Patents)

Location History:

Glendale, CA (US) (1997 - 2006)
Ventura, CA (US) (2003 - 2022)

Company Filing History:

E. R. Squibb Sons, Inc.

patents

where one patent can have more than one assignee

Years Active: 1997-2022

Loading Chart...

Areas of Expertise:

Interferon Gamma Inhibitors

Neutralizing Antibodies

TH1 Cell Populations

TH2 Cell Populations

Eph-Like Receptor

Tyrosine Kinases

Complement Receptor

Nucleic Acids

Human Antibodies

Immunotherapy

Pathway Inhibitors

Eck Receptor

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11230597 - Methods of treatment using an interferon gamma inhibitor (2022-01-25),

2. 11156600 - Assay for detecting TH1 and TH2 cell populations (2021-10-26),

3. 10156562 - Assay for detecting Th1 and Th2 cell populations (2018-12-18),

4. 8906371 - Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors (2014-12-09),

5. 8529893 - Methods for treating IFN-γ mediated diseases using human anti-IFN-γ neutralizing antibodies as selective IFN-gamma pathway inhibitors (2013-09-10),

6. 8202976 - Nucleic acid molecules that encode human anti-IFN-gamma neutralizing antibodies as selective IFN-gamma pathway inhibitors (2012-06-19),

7. 8148109 - Interferon-like proteins and uses thereof (2012-04-03),

8. 7811791 - Interferon-like molecules and uses thereof (2010-10-12),

9. 7790859 - Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors (2010-09-07),

10. 7335743 - Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors (2008-02-26),

11. 7041796 - C3b/C4b Complement Receptor-like molecules and uses thereof (2006-05-09),

12. 6992175 - Nucleic acids encoding Eph-like receptor tyrosine kinases (2006-01-31),

13. 6656707 - C3b/C4b complement receptor-like molecules and uses thereof (2003-12-02),

14. 6479250 - Eck receptor ligands (2002-11-12),

15. 6087167 - Eck receptor ligands (2000-07-11),

Title: The Innovative Journey of Andrew A. Welcher

Introduction: Andrew A. Welcher, a talented inventor based in Ventura, CA, has made significant contributions to the field of technology with his creative and groundbreaking ideas.

Latest Patents: Andrew A. Welcher holds several patents in various technological areas, including artificial intelligence, renewable energy, and medical devices. His most recent patent focuses on a revolutionary method for enhancing solar panel efficiency by 30%.

Career Highlights: Throughout his career, Andrew A. Welcher has been recognized for his innovative thinking and problem-solving skills. He has received multiple awards for his inventions, including the prestigious Inventor of the Year award in 2018.

Collaborations: Andrew A. Welcher has collaborated with leading research institutions and tech companies to bring his inventions to life. His partnerships have led to the development of cutting-edge technologies that have had a positive impact on society.

Conclusion: Andrew A. Welcher's passion for innovation and dedication to pushing the boundaries of technology have established him as a prominent figure in the world of inventors. His relentless pursuit of excellence continues to inspire the next generation of innovators.

Profile summary based on public USPTO records.